Pricing Log in Create free account

Aardvark Therapeutics, Inc. (AARD) vs Novogen Limited (KZIA)

Aardvark Therapeutics, Inc. and Novogen Limited are both Biotechnology companies. Aardvark Therapeutics, Inc. and Novogen Limited are of similar size ($84.6M and $84.5M). Across the 9 metrics below, Novogen Limited leads on 7 and Aardvark Therapeutics, Inc. on 2.

Valuation

Metric AARD KZIA Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 1.10 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 1.46 0.64
EV/Sales n/m n/m 9.21
Earnings yield (84.92%) (2.98%) (33.15%)
Free cash flow yield (84.17%) 0.00% (25.50%)

Profitability

Metric AARD KZIA Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (66.02%) 0.00% (56.36%)
Return on assets (61.06%) 0.00% (48.04%)
Return on invested capital (4,986.18%) 0.00% 0.00%

Growth

Metric AARD KZIA Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 43.11% 63.24% 30.26%
Revenue growth, 5-year CAGR — 11.56% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AARD KZIA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.63 2.87 4.72
Net debt to EBITDA 1.72 0.30 0.96

Dividend

Metric AARD KZIA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AARD KZIA Biotechnology median
Market cap 84.47m 84.58m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack